Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)
- Conditions
- Interventions
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2024-01-17
- Target Recruit Count
- 66
- Registration Number
- NCT03875144
- Locations
- 🇫🇷
Institut réginal du Cancer de Montpellier, Montpellier, France
Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
- Conditions
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 36
- Registration Number
- NCT03872661
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Akeso
- Target Recruit Count
- 164
- Registration Number
- NCT03866980
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
🇨🇳Shanghai Chest Hospital, Shanghai, Shanghai, China
A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.
- Conditions
- Interventions
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Xin-Hua Xu
- Target Recruit Count
- 70
- Registration Number
- NCT03863483
- Locations
- 🇨🇳
Department of Medical Oncology, Central Hospital of Yichang City, the First Clinical Medical College of Three Gorges University, Yichang, Hubei, China
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study
- Conditions
- Interventions
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 262
- Registration Number
- NCT03850444
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT03846310
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Korea, Republic of
🇰🇷Bundang CHA Medical Center, Seongnam-si, Korea, Republic of
🇰🇷Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer
- Conditions
- Interventions
- Locations
- 🇨🇳
the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2023-08-21
- Target Recruit Count
- 70
- Registration Number
- NCT03840915
- Locations
- 🇺🇸
Compassionate Care Research Group Inc - Edinger Medical Group, Inc., Fountain Valley, California, United States
🇺🇸RCCA MD LLC - Bethesda, Bethesda, Maryland, United States
🇺🇸University of Maryland - DUPLICATE/Pediatric Surgery, Baltimore, Maryland, United States
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-01-16
- Target Recruit Count
- 153
- Registration Number
- NCT03840902
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center - Unit 432 Thoracic Head and Neck Medical Oncology, Houston, Texas, United States
🇺🇸Lynn Cancer Institute Center, Boca Raton, Florida, United States
🇺🇸American Health Network of Indiana, LLC, Indianapolis, Indiana, United States
KN046 in Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT03838848
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.